van Gelder, Mde Wreede, L CBornhäuser, MNiederwieser, DKaras, MAnderson, N SGramatzki, MDreger, PMichallet, MPetersen, EBunjes, DPotter, MBeelen, DCornelissen, J JYakoub-Agha, IRussell, N HFinke, JSchoemans, HVitek, AUrbano-Ispízua, ÁBlaise, DVolin, LChevallier, PCaballero, DPutter, Hvan Biezen, AHenseler, ASchönland, SKröger, NSchetelig, J2025-01-072025-01-072016-12-12https://hdl.handle.net/10668/25107Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.enAdolescentAdultAge FactorsAgedAllograftsChildDisease-Free SurvivalEuropeFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedSocieties, MedicalSurvival RateTime Factorsresearch article27941763open access10.1038/bmt.2016.2821476-5365https://www.nature.com/articles/bmt2016282.pdf